Antineoplaston Therapy in Treating Patients With Neurofibroma and Schwannoma
Status:
Terminated
Trial end date:
2001-08-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Current therapies for adults with a recurrent/residual Neurofibroma or Schwannoma
provide limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy
suggest that it may prove beneficial in the treatment of adults with a recurrent/residual
Neurofibroma or Schwannoma.
PURPOSE: This study is being performed to determine the effects (good and bad) that
Antineoplaston therapy has on adults with a recurrent/residual Neurofibroma or Schwannoma.